166 reports of this reaction
1.5% of all BRIMONIDINE reports
#11 most reported adverse reaction
VISION BLURRED is the #11 most commonly reported adverse reaction for BRIMONIDINE, manufactured by Padagis Israel Pharmaceuticals Ltd. There are 166 FDA adverse event reports linking BRIMONIDINE to VISION BLURRED. This represents approximately 1.5% of all 11,162 adverse event reports for this drug.
Patients taking BRIMONIDINE who experience vision blurred should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISION BLURRED is a less commonly reported adverse event for BRIMONIDINE, but still significant enough to appear in the safety profile.
In addition to vision blurred, the following adverse reactions have been reported for BRIMONIDINE:
The following drugs have also been linked to vision blurred in FDA adverse event reports:
VISION BLURRED has been reported as an adverse event in 166 FDA reports for BRIMONIDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISION BLURRED accounts for approximately 1.5% of all adverse event reports for BRIMONIDINE, making it a notable side effect.
If you experience vision blurred while taking BRIMONIDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.